Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 48,833 shares at $1.69 ($83K) on 2012-11-15, disclosed to the SEC on 2012-11-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| PGNX | BUY | 2013-01-23 | $3K | — | Filing → |
| PGNX | BUY | 2012-12-26 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-30 | $3K | — | Filing → |